CSPC PHARMA (01093.HK): Gets USD 15m CRB-701 Milestone Payment

On 19 November 2026, CSPC PHARMA (01093.HK) said its unit received a USD 15 million CRB-701 milestone payment from Corbus, bringing total to USD 32.5 million.

NewTimeSpace News: On 19 November 2026, CSPC Pharmaceutical Group Limited (stock code: 01093.HK) announced that its subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., received a development milestone payment of USD 15 million from Corbus Pharmaceuticals, Inc. on 18 November 2026.

The payment was made under an exclusive license agreement dated 13 February 2023. The product, CRB-701 (SYS6002), is a next-generation antibody-drug conjugate (ADC) targeting Nectin-4. CSPC Megalith granted Corbus an exclusive license to develop and commercialise the product in the territory.

As at the date of the announcement, CSPC Megalith had received upfront and development milestone payments of USD 32.5 million in aggregate under the agreement. The company said the milestone indicated that the related research and development work was progressing as planned, and cautioned that development and commercialisation of the product remain subject to uncertainties.

×
Share to WeChat

Open WeChat, use the "Scan", and share to my Moments.